Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Elizabeth Brem, Wojciech Jurczak, David Belada, Jaime Perez de Oteyza, Aranzazu Alonso Alonso, Fevzi Altuntas, Michał Kwiatek, Joshua Brody, Ernesto Perez Persona, Mustafa Yenerel, Monica Tani, Jingxian Cai, Priya Deshpande, Saleem Shariff, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Ashish Risal, Ruemu Birhiray

Blood (2024) 144 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2024-200080

Published: 2024

Journal Articles

Deep Characterization of Immune Dysfunction in Patients with Multiple Myeloma (MM) and Identification of Cellular Biomarkers for Tailored Vaccination Strategies

Blood (2023) 142 (Supplement 1): 643.

https://doi.org/10.1182/blood-2023-181747

Published: 2023

Journal Articles

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Perez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Johannes Duell, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Maren Dirnberger-Hertweck, John M. Burke, Grzegorz S. Nowakowski

Blood (2023) 142 (16): 1348–1358.

https://doi.org/10.1182/blood.2023020637

Published: 2023

Includes: Supplemental data

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

SLFN11 Is a Potential Biomarker and Modulator of Treatment Response in AML

Sara Small, Mariafausta Fischietti, Elspeth Beauchamp, Ricardo Ernesto Perez, Leonidas C. Platanias

Blood (2022) 140 (Supplement 1): 9098–9099.

https://doi.org/10.1182/blood-2022-162444

Published: 2022

Journal Articles

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Blood (2022) 140 (Supplement 1): 9908–9910.

https://doi.org/10.1182/blood-2022-162186

Published: 2022

Journal Articles

First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Pérez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Bettina Brackertz, Neha Shah, Andrea Sporchia, John M. Burke, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 3556.

https://doi.org/10.1182/blood-2021-148354

Published: 2021

Journal Articles

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Blood (2021) 138 (Supplement 1): 1561.

https://doi.org/10.1182/blood-2021-147685

Published: 2021

Journal Articles

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Pau Abrisqueta Costa, Javier Loscertales, MD, Maria Jose Terol, Angel Ramirez Payer, Macarena Ortiz Pareja, Inmaculada Perez, Carolina Cuellar, Margarita Fernandez De La Mata, Alicia Rodriguez, MD, Ana Lario, Julio Delgado, MD, Ana Cristina Godoy, PhD, Jose M Arguiñano, Maria José Berruezo, Ana C Oliveira, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, María-Dolores García-Malo, MD, Angeles Medina, MD, Paloma García Martín, Santiago Osorio-Prendes, MD, Patricia Baltasar, Miguel Fernandez, MD, Fernando Marco, María-Jesús Vidal, Alicia Susana Smucler Simonovich, Montserrat Lopez Rubio, PhD, Isidro Jarque, Alexia Suárez Cabrera, Ruben Fernandez, MD, Aima Lancharro Anchel, Eduardo Rios Herranz, Carmen Losada, Ernesto Pérez Persona, Ricardo Francisco Garcia, Dr., Rafael Ramos, Lucrecia Yáñez, MD PhD, Jose Luis Bello, MD, Cristina Loriente, Miguel Villanueva

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136036

Published: 2020

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

David Belada, MD PhD, Grzegorz S. Nowakowski, MD, Juan Miguel Bergua Burgues, MD, Marc André, MD, Katerina Kopeckova, MD, Don A. Stevens, MD, Marek Trněný, MD Prof, Ernesto Pérez Persona, Petra Pichler, Pia Klöpfer, Bettina Brackertz, Emanuel Lohrmann, MD, Anirban Lahiry, Neha Shah, Günter Fingerle-Rowson, MDPhD, Wolfram Brugger, John M. Burke, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139788

Published: 2020

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Treatment Burden in Patients with Multiple Myeloma According to Comorbidity

Ernesto Pérez Persona, Ariane Unamunzaga Cilaurren, Ana Vega Gonzalez de Viñaspre, Itziar Oiartzabal Ormategui, Ana Santamaría Lopez, Laida Cuevas Palomares, Diego Robles de Castro, Carlos de Miguel Sanchez, Miren Gabilondo Jalón, Angel Pereda Vicandi, Arantza Mendizábal, Jose María Guinea de Castro

Blood (2018) 132 (Supplement 1): 4775.

https://doi.org/10.1182/blood-2018-99-112970

Published: 2018

Journal Articles

Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Blood (2017) 130 (Supplement 1): 4321.

https://doi.org/10.1182/blood.V130.Suppl_1.4321.4321

Published: 2017

Journal Articles

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Blood (2017) 130 (Supplement 1): 1624.

https://doi.org/10.1182/blood.V130.Suppl_1.1624.1624

Published: 2017

Journal Articles

Safety and Eficacy of Low Dose- Bortezomib Plus Melphalan/Prednisone (velcadito protocol) in Elderly Patintes Not Eligible to Transplant in Newly Dignosed Multiple Myeloma. Restrospective Study of 26 Patients

Breno Moreno Gusmão, MD, Danielle Isadora Blumenschein, MD, Ernesto Perez Persona, MD- PhD, Jose Maria Guinea De Castro, MD, Iracema Esteves Lopes, MD PhD, Nelson Hamerschlak, MD PhD

Blood (2016) 128 (22): 5710.

https://doi.org/10.1182/blood.V128.22.5710.5710

Published: 2016

Journal Articles

Validation Of a Comprehensive Health Status Assessment Scale In Older Patients (≥ 65 years) With Hematological Malignances. Gah Study

Blood (2013) 122 (21): 2979.

https://doi.org/10.1182/blood.V122.21.2979.2979

Published: 2013

Journal Articles

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Blood (2010) 116 (21): 2448.

https://doi.org/10.1182/blood.V116.21.2448.2448

Published: 2010

Journal Articles

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

Ernesto Pérez-Persona, María-Belén Vidriales, Gema Mateo, Ramón García-Sanz, Maria-Victoria Mateos, Alfonso García de Coca, Josefina Galende, Guillermo Martín-Nuñez, José M. Alonso, Natalia de las Heras, José M. Hernández, Alejandro Martín, Consuelo López-Berges, Alberto Orfao, Jesús F. San Miguel

Blood (2007) 110 (7): 2586–2592.

https://doi.org/10.1182/blood-2007-05-088443

Published: 2007

Journal Articles

New Criteria To Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance: Multiparametric Flow Cytometry Analysis of Bone Marrow Plasma Cells.

Ernesto Perez-Persona, MD, María-Belén Vidriales, MD,PhD, Gema Mateo, PhD, Ramón Garcia Sanz, MD,PhD, Marivi Mateos, MD,PhD, Alfonso Garcia de Coca, MD, Josefina Galende, MD,PhD, Guillermo Martin-Nunez, MD, Jose M. Alonso, MD, Natalia Heras, MD, Jose M. Hernandez, MD,PhD, Alejandro Martin, MD,PhD, Consuelo Lopez-Berges, MD,PhD, Alberto Orfao, MD,PhD, J.F. San Miguel, MD,PhD

Blood (2006) 108 (11): 3517.

https://doi.org/10.1182/blood.V108.11.3517.3517

Published: 2006

NARROW

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Deep Characterization of Immune Dysfunction in Patients with Multiple Myeloma (MM) and Identification of Cellular Biomarkers for Tailored Vaccination Strategies

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

SLFN11 Is a Potential Biomarker and Modulator of Treatment Response in AML

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Treatment Burden in Patients with Multiple Myeloma According to Comorbidity

Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Safety and Eficacy of Low Dose- Bortezomib Plus Melphalan/Prednisone (velcadito protocol) in Elderly Patintes Not Eligible to Transplant in Newly Dignosed Multiple Myeloma. Restrospective Study of 26 Patients

Validation Of a Comprehensive Health Status Assessment Scale In Older Patients (≥ 65 years) With Hematological Malignances. Gah Study

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

New Criteria To Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance: Multiparametric Flow Cytometry Analysis of Bone Marrow Plasma Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only